The round was led by Boston Scientific Corporation with participation from existing investors RiverVest Venture Partners, 3X5 Special Opportunity Fund, and the University of Michigan MINTS program, as well as another new investor the Global Cardiovascular Innovation Center.
The company intends to use the funds for continued product development and clinical investigation of the its recently FDA cleared infrared thermographic system [IRTS].
Led by Steven Girouard, President and CEO, Securus is developing real-time, noncontact, thermal mapping systems to determine intrabody tissue temperatures. Its IRTS is a proprietary, intrabody thermal measurement device that is intended for continuous esophageal temperature monitoring.
The company maintains administrative headquarters at Cleveland Clinic’s Global Cardiovascular Innovation Center and has R&D operations in Massachusetts.